|
|
|
|
|
|
|
Neuralstem, U-Mich., Collaborate On Potential Lou Gehrig’s Disease Treatment
Tuesday, September 04, 2007
- Stem Cell Business News |
|
|
Rockville, Md.-based stem cell company Neuralstem, Inc. (CUR) said on August 30 that it will work with the ALS Clinic at the University of Michigan to develop further proof-of-principle data to move the company’s spinal cord stem cells into patients with amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease.
ALS is a progressive, fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.
As many as 30,000 Americans have the disease.
Neuralstem says its technology enables production of neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.
Contact: http://www.neuralstem.com
Scroll down to see related articles below.
|
|
Related
Articles :
- Neuralstem Licenses Out Compounds For Diabetes Treatment (Thursday, January 11, 2007)
A Maryland stem cell company has given a license to a firm to develop several compounds to treat certain cognitive and neurological impacts of diabetes.
- Human Neural Stem Cell Grafts Differentiate In Adult Rat Spinal Cord (Monday, February 12, 2007)
Human neural stem cell grafts can show neuronal differentiation in the normal and injured spinal cord of adult rats, according to researchers.
- Neuralstem Raises $5 Million In Private Placement (Friday, March 16, 2007)
Neuralstem has raised $5 million in a private placement to a group of institutional investors.
- Company’s Human Stem Cell Treatment Restores Motor Function In Paralyzed Rats (Thursday, May 31, 2007)
Rats paralyzed due to loss of blood flow to the spine returned to near normal ambulatory function six weeks after receiving grafts of human spinal stem cells (hSSCs), researchers report.
- Stem Cell Patent Infringement Suit On Hold Pending USPTO Re-examination (Friday, July 06, 2007)
The two companies involved in a stem cell-related patent infringement lawsuit have agreed to a stay of the proceedings until the U.S. Patent & Trademark Office re-examines the patents in question.
- Neuralstem Shares To Trade On Amex Exchange (Friday, August 24, 2007)
Neuralstem's stock will begin trading on the American Stock Exchange on August 27.
|
|
|
|
|
|
|
|
| |
|
 |
|
|
|
|
 |
